Content Type: Commentary & Opinion

Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms

March 6, 2026

The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence

March 6, 2026

Battles Over Medication Abortion Threaten the Integrity of Drug Approvals in the US

March 6, 2026

Authority of Medicare to Limit Coverage of FDA-Approved Products: Legal and Policy Considerations

March 6, 2026

The Accelerated Approval Program for Cancer Drugs—Finding the Right Balance

March 6, 2026

Op-Ed: How the Makers of Inhalers Keep Prices So High

March 6, 2026

High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions

March 6, 2026

Medicare Drug Price Negotiation: Few Drugs, Big Impact?

March 6, 2026

The Rise and Fall of the Insulin Pricing Bubble

March 6, 2026

Op-Ed: New Alzheimer’s Drug Is a Problem for FDA’s Pass-Fail Approach

March 6, 2026

Congress’ Misguided Plan to Ban QALYs

March 6, 2026

Op-Ed: Registry Enrollment for Alzheimer’s Drug Coverage Won’t Help Much

March 6, 2026